Last reviewed · How we verify

Fuji Yakuhin Co., Ltd. — Portfolio Competitive Intelligence Brief

Fuji Yakuhin Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FYU-981 FYU-981 phase 3
FFI-1010 FFI-1010 phase 3 BTK inhibitor BTK Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. AstraZeneca · 2 shared drug classes
  3. Eli Lilly and Company · 2 shared drug classes
  4. GlaxoSmithKline · 2 shared drug classes
  5. Pierre Fabre Medicament · 2 shared drug classes
  6. AceLink Therapeutics, Inc. · 1 shared drug class
  7. Abbott · 1 shared drug class
  8. AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fuji Yakuhin Co., Ltd.:

Cite this brief

Drug Landscape (2026). Fuji Yakuhin Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fuji-yakuhin-co-ltd. Accessed 2026-05-17.

Related